Literature DB >> 8163991

Motor response to levodopa in patients with parkinsonian motor fluctuations: a follow-up study over three years.

A J Hughes1, J P Frankel, P A Kempster, G M Stern, A J Lees.   

Abstract

To clarify the way in which the clinical response to levodopa changes with the progression of Parkinson's disease, a longitudinal study was performed to quantify motor response characteristics to single doses of levodopa by mouth over three years in 23 patients with fluctuating motor function. A significant increase in motor disability in "on" (time of peak motor improvement) and "off" (before levodopa dose) phases occurred and "on" phase dyskinesia increased by 24%, though the amplitude of motor response was conserved. There was no evidence of progressive loss of response of certain motor deficits affecting axial muscles and gait. The mean duration of motor response decreased by 17%. Both shortening of response duration and increase in "off" phase disability contribute to the development of motor fluctuations. A short response time to the levodopa test dose was not an invariable finding in patients with severe fluctuations, whereas all had large response amplitudes and high "off" phase disability scores. Patients who have developed motor fluctuations may continue to respond to dopaminergic treatment until late in the disease course, despite the unstable nature of their responses.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8163991      PMCID: PMC1072871          DOI: 10.1136/jnnp.57.4.430

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  9 in total

1.  Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions?

Authors:  A M Bonnet; Y Loria; M H Saint-Hilaire; F Lhermitte; Y Agid
Journal:  Neurology       Date:  1987-09       Impact factor: 9.910

2.  Treatment of parkinsonism with L-dopa (study of 105 patients).

Authors:  H L Klawans; J S Garvin
Journal:  Dis Nerv Syst       Date:  1969-11

3.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

4.  Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease.

Authors:  P A Kempster; J P Frankel; M Bovingdon; R Webster; A J Lees; G M Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

5.  Bradyphrenia in Parkinson's disease and psychomotor retardation in depressive illness. An experimental study.

Authors:  D Rogers; A J Lees; E Smith; M Trimble; G M Stern
Journal:  Brain       Date:  1987-06       Impact factor: 13.501

6.  Does ageing aggravate parkinsonian disability?

Authors:  J Blin; B Dubois; A M Bonnet; M Vidailhet; M Brandabur; Y Agid
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-09       Impact factor: 10.154

7.  Result of chronic levodopa therapy and its modification by bromocriptine in Parkinson's disease.

Authors:  M M Hoehn
Journal:  Acta Neurol Scand       Date:  1985-02       Impact factor: 3.209

8.  The impact of treatment with levodopa on Parkinson's disease.

Authors:  K M Shaw; A J Lees; G M Stern
Journal:  Q J Med       Date:  1980

9.  Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease.

Authors:  G Fabbrini; J Juncos; M M Mouradian; C Serrati; T N Chase
Journal:  Ann Neurol       Date:  1987-04       Impact factor: 10.422

  9 in total
  8 in total

1.  Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.

Authors:  C Colosimo; M Merello; A J Hughes; K Sieradzan; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

Review 2.  Transdermal treatment options for neurological disorders: impact on the elderly.

Authors:  Lorenzo Priano; Maria Rosa Gasco; Alessandro Mauro
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 3.  Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease.

Authors:  J Kulisevsky
Journal:  Drugs Aging       Date:  2000-05       Impact factor: 3.923

4.  Motor phenotype classification in moderate to advanced PD in BioFIND study.

Authors:  Lan Luo; Howard Andrews; Roy N Alcalay; Fernanda Carvalho Poyraz; Amelia K Boehme; Jennifer G Goldman; Tao Xie; Paul Tuite; Claire Henchcliffe; Penelope Hogarth; Amy W Amara; Samuel Frank; Margaret Sutherland; Catherine Kopil; Anna Naito; Un Jung Kang
Journal:  Parkinsonism Relat Disord       Date:  2019-06-23       Impact factor: 4.891

5.  Evaluation of morning bradykinesia in Parkinson's disease in a United States cohort using continuous objective monitoring.

Authors:  S H Isaacson; R Pahwa; E J Pappert; D Torres-Russotto
Journal:  Clin Park Relat Disord       Date:  2022-05-17

6.  Do neuropsychiatric fluctuations temporally match motor fluctuations in Parkinson's disease?

Authors:  Eleonora Del Prete; Emmanuelle Schmitt; Sara Meoni; Valerie Fraix; Anna Castrioto; Pierre Pelissier; Roberto Ceravolo; Elena Moro
Journal:  Neurol Sci       Date:  2022-01-19       Impact factor: 3.307

7.  An objective fluctuation score for Parkinson's disease.

Authors:  Malcolm K Horne; Sarah McGregor; Filip Bergquist
Journal:  PLoS One       Date:  2015-04-30       Impact factor: 3.240

8.  Investigating emotions in Parkinson's disease: what we know and what we still don't know.

Authors:  Igor Sotgiu; Maria L Rusconi
Journal:  Front Psychol       Date:  2013-06-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.